Alkermes - Articles and news items

FDA approves schizophrenia treatment Aristada

Industry news / 7 October 2015 / Victoria White

Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection…

Alkermes logo

Alkermes announces positive topline results from phase 1 study of ALKS 8700 for treatment of multiple sclerosis

Industry news / 9 February 2015 / Alkermes plc

Alkermes plc announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis…

Alkermes logo

Alkermes initiates phase 3 clinical study of ALKS 9070 for treatment of schizophrenia

Industry news / 20 December 2011 / Alkermes

ALKS 9070 is designed to offer once-monthly version of Aripiprazole…

Eli Lilly logo
Eli Lilly logo

BYDUREON™ receivies marketing authorisation in Europe

Industry news, News / 21 June 2011 / Eli Lilly and Company

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to BYDUREON™…

Alkermes to merge with Elan Drug Technologies to create Alkermes plc

Industry news, News / 9 May 2011 / Elan Drug Technologies (EDT)

Alkermes will merge with EDT in a cash and stock transaction currently valued at approximately $960 million…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...